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Abstract
Purpose of Review The purpose of this study was to review
the current evidence for quality of life (QOL) in patients with
kidney stone disease (KSD).
Recent Findings A review of literature from inception to
May 2016 for all prospective English language articles on
QOL in patients with KSD was done. QOL studies post
urological procedures or ureteric stents were excluded.
Nine studies (1570 patients) were included of which most
(n = 6) used the SF-36 QOL tool. Overall, seven of the
nine studies demonstrated a lower QOL in patients with
KSD. Bodily pain and general health were significantly
lower in patients with KSD compared to their control
groups.
Summary Patients with KSD have an overall lower QOLwith
most impact on bodily pain and general health domains.
Compared to the scale of patients suffering from KSD, more
work needs to be done in measuring QOL both in terms of
‘Stone specific’ QOL measuring tools and the quality/number
of studies in this field.
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Introduction
Kidney stone disease (KSD) is a common problem, affecting
approximately 10–15 % of people in Europe and North
America [1•]. In the USA, the lifetime prevalence for men is
12 %, and for women, it is 6 % [2]. Stone formers are 50 %
more likely to have a further stone in the following 5 years [3].
Although some patients are asymptomatic with their KSD,
many will have pain, urinary tract infection (UTI) or
haematuria and may require multiple hospital admissions or
multiple surgical procedures for this. This may also affect their
renal function with an impact on their quality of life (QOL).
There are numerous ways to treat renal tract calculi, de-
pending on their size, location, volume, anatomical factors
and patient comorbidities. Historically, it was open surgical
techniques; shock wave lithotripsy (SWL) was introduced in
1980, followed by percutaneous nephrolithotomy (PCNL)
and subsequently endourological techniques with the
popularisation of ureteroscopy (URS). After any one of these
procedures, especially ureteroscopy, a ureteric stent may need
to be placed. The presence of KSD, interventions for it and/or
ureteric stents can all influence the QOL to varying degrees
[4–10].
Patients with KSD can have increased levels of bodily pain,
depression, loss of days at work and increased anxiety and
financial distress, leading to overall lower QOL scores
[11–15, 16••]. How KSD and its treatments affect QOL may
affect patient or surgeon decisions regarding the management
of their KSD [15]. The impact of KSD on patients’ QOL is
becoming increasingly important to consider, as the focus of
treatment has shifted not just only from considering morbidity
and mortality but also considering the impact on their QOL
[17–22, 23•].
Quality of life is a subjective experience and hence makes
the effective measurement difficult. It is important to consider
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patients’ QOL, as it can help us understand how the disease
affects their day to day living, and the personal burden of
illness. This is not always related to the severity of their dis-
ease, by laboratory values or imaging, but by how the disease
and possibly its treatment are perceived by the patient [18].
There are many psychosocial factors that need to be taken into
consideration as well as symptom-related aspects of QOL.
Examples of these are financial difficulties, stresses from
job, family and associated pain [5]. There are a multitude of
designed and validated tools used to measure this [5–8]. It is
important for patients to assess their own QOL, not for health
professionals to try and assume what it might be. Measuring
QOL is important as one of the aims of any treatment is for the
patient to feel and function normally. Using the information
gathered fromQOL studies, patients can be better informed on
their treatment options and how they may fair after different
treatments. Over the last 30 years, improving patients QOL
has become an increasingly important part of treatment, and
therefore, many tools have been produced to measure this
[5–8]. However, there are currently no validated KSD-
specific QOL tools available [15].
We conducted a systematic review of literature to look at
the tools used for measuring QOL and the aspects of patients
QOL most affected by KSD.
Materials and Methods
Evidence Acquisition
Criteria for Studies to Be Included in This Review
Inclusion Criteria
& Prospective studies written in the English language from
inception to May 2016
& Studies reporting on QOL in patients with KSD
Exclusion criteria
& QOL studies of patients with ureteric stents
& QOL studies immediately after any urological procedure
Our aim was to look at the impact of KSD on patients’
QOL, which domains were affected, and to see which QOL
tools were commonly used in urolithiasis patients.
Search Strategy
The systematic review was performed according to the
Cochrane reviews guidelines and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [9]. We searched Pubmed,
MEDLINE, EMBASE, Scopus, CINAHL, Cochrane library,
Clinicaltrials.gov, Google Scholar and individual urological
journals from inception to May 2016, and all English lan-
guage articles were included in the original search. The search
terms included: ‘Quality of life’, ‘kidney stone disease’, ‘uro-
lithiasis’, ‘calculi’, ‘stones’ and ‘nephrolithiasis’. Boolean op-
erators (AND, OR) were used with the above search terms to
refine the search. Studies reporting on QOL in patients with
KSD were included but studies on QOL in patients with ure-
teric stents or immediately after any surgical intervention were
excluded. Data was extracted for the type of study, country of
origin, review period, patient demographics, QOL tools used,
domains measured and their effect on QOL.
Results
Literature Search and Included Studies
After an initial search of 145 articles, 9 (1570 patients) met the
inclusion criteria for the final review (Fig. 1). These were
published from 2007 onwards, with six studies being from
the USA. A full breakdown can be seen in Table 1.
Patient Characteristics and QOL tools used
In total, there were 1570 patients, with a mean age of 50 years
(range 18–88 years). There was an even male to female distribu-
tion of 1:1. Most studies used the SF-36 QOL tool [11–14, 18,
23•] while two studies developed, and used a tool named the
‘Winsicon stone QOL tool’ [5, 15]. The final study used the
Emory stone questionnaire (an aid to collect patient demographics,
information about stones and procedures) and the CES-D depres-
sion questionnaire [16••, 24]. Eight of the studies were prospective
in nature, all being level 2a/b in their evidence quality.
Primary Outcomes
QOL Questionnaires Used
The main QOL tool used was the SF-36 questionnaire [11–14,
18, 23•]. It consists of 36 questions, which asses eight QOL
domains; physical function (PF), role physical (RP), bodily
pain (BP), general health (GH), Virility (V), social factors
(SF), role-emotional (RE) and mental health (MH). It asks
how these factors affected their life in the month preceding
the questionnaire [5]. The three other studies used the
Winsicon stone QOL tool [5, 16••] and the Centre for
Epidemiologic Studies Depression Scale (CES-D) [15, 24].
The Winsicon stone QOL tool has 28 questions, which cov-
ered similar QOL aspects but also specifically asked about
urinary frequency, dysuria and nocturia. The CES-D depres-
sion questionnaire is a 20-question survey used to illicit if
patients have depressive symptoms.
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Domains of QOL Measured
Six of the nine studies [11–14, 18, 23•] used the SF-36 ques-
tionnaire, a generic QOL tool, which divides patients QOL
into eight domains. Five of these studies [12–14, 18, 23•]
compared different QOL domains of patients with KSD to a
case control group, or to the average QOL of the matched
population. Four of these studies [13, 14, 18, 23•] reported
the QOL scores for each domain (Table 2). Of these four, all
demonstrated a lower QOL in patients with KSD, with Denise
et al. demonstrating a statistically significant difference in all
eight domains [14]. Byrant et al. showed a lower QOL in six
of the eight domains (Physical Health, Bodily pain, General
Health, Virility, Sexual Function) [18], while Kristina et al.
showed lower QOL in general health and bodily pain [13].
Modersitzki et al. demonstrated a statistical significance in all
eight domains within 1 month of a stone episode, with scores
rising (QOL improving) over time from this episode [23•].
Bensalah et al. demonstrated significantly lower scores in five
domains, including role physical, bodily pain, general health,
social function and physical function [12].
The other three studies used alternative QOL tools. Angell
et al. demonstrated clinically significant depression in 30.4 %
of their patients with urolithiasis, where clinical depression was
characterised as a CES-D score of 16 or more [16••]. The last
two studies developed and used a specific QOL tool for patients
Fig. 1 Inclusion criteria for final
review of patients
Table 1 All studies reporting on KSD (included in our review)
Author Year
published
Journal Review
period
M:F Mean age
(years)
Patient
number
QOL
tool used
Chester J. Donnally III [11] 2011 Urology Research 2007–2009 1:1 51 152 SF-36
Kristina L. Penniston [16••] 2013 The Journal of Urology 2012 1:6 51 248 Winsicon
stone QOL
Margaret S. Pearle and Yair Lotan [12] 2008 The Journal of Urology 2007 7:3 51 155 SF-36
Kristina L. Penniston and Stephen
Y. Nakada [13]
2007 The Journal of Urology 1995–2006 1:1 51 189 SF-36
Jordan Angell, Michael Bryant [15] 2011 Journal of Urology 2005–2010 3:2 53 115 Emory stone
questionnaire
+ CES-D
Denise H.M.P. Diniza Sérgio Luís Blay [14] 2007 Nephron Clinical Practice 2001–2004 1:2 44 194 SF-36
Bryant B, Angell J [18] 2012 The Journal of Urology 2005–2010 1:1 53 115 SF-36
Penniston KL [22] 2016 Journal of Endourology 2012 1:1 53 107 Winsicon stone QOL
Moderstikizi, F [23•] 2014 Urolithiasis 2014 1:1 47 295 SF36
Total: 1:1 50 1570
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with urinary tract stones. It contained 28 questions, looking at
areas including irritability, fatigue, social impact, virility, uri-
nary frequency and urgency, general health, physical pain and
difficulty sleeping [16••]. Kristina et al. demonstrated that pa-
tients with active stones scored lower for the sum total of the
questionnaire, than those who where asymptomatic [16••]. In
the asymptomatic stone group, those with stones still scored
lower in urinary frequency, urgency, general anxiety or ner-
vousness about the future (p < 0.027) [5].
Association Between Stone Episode and Time
to Questionnaire Completion
Three out of the six studies documented average time from pre-
vious stone episode to questionnaire completion [12, 15, 16••].
The average time from these studies was 13 months (range 1–
37 months). One study showed stability of SF-36 in KSD pa-
tients over a median follow-up of 18 months; however, a small
cohort (n = 18) who had an acute stone episode within a month
of completing their first questionnaire showed no significant
differences in scores compared to other patients (n = 75) [11].
Byrant et al. demonstrated a significantly lower QOL for
bodily pain and physical health domains in patients who had
stone episode <1 month from completing the questionnaire
[18]. A study on cysteine stone patients suggested that QOL gets
better over a period of time and the timing of SF-36 needs to be
accounted for when interpreting the domain scores and treat-
ment, especially in patients with previous stone episodes [23•].
Association Between Previous Stone-Related Procedure
and QOL
Of the nine studies, two did not document any previous surgery
for KSD [14, 15]. Seven studies documented previous surgical
procedures for KSD, with an average of 64 % (43–80 %) of
patients having prior stone surgery [5, 11–15, 23•]. Most sug-
gest improvement of QOL over time especially in patients who
suffered a recent or previous stone episode. Bensalah et al.
analysed 155 patients from their clinic and found that the num-
ber of previous surgical interventions and body mass index had
most affect on QOL especially their physical and mental com-
ponents [12]. Similarly, another study using the SF-36 ques-
tionnaires on 115 patients suggested that the number of surger-
ies and surgical complications, time to stone episodes and the
number of emergency room visits correlated most with the SF-
36 physical and mental domains [18].
Discussion
Findings of Our Study
Overall, seven of the nine studies demonstrated a lower QOL in
patients with KSD. Bodily pain and general health was signif-
icantly lower in patients with KSD compared to their control
groups. There seems to be a correlation between stone episodes
and QOL, and this seems to improve with the passage of time.
Similarly, previous surgical intervention seems to have a nega-
tive impact on their QOL, as compared to the control group.
Importance of Measuring QOL in KSD Patients
Patients with KSD tend to have a lower QOL even in the
absence of stone episodes or interventions. It might reflect
their previous experience of stone disease or an apprehension
of the need for further treatment. Measurement of QOL is
important to understand the impact of psychosocial and phys-
ical aspects of the disease. It can aid us in advising which
management option may be more suitable for the individual.
Only a longer-term follow-up over a few years would help us
determine the time taken for the QOL domains to get back to
baseline. QOL measurements also help us to evaluate and see
ways in which we can improve our surgical choices or tech-
nique to improve patients’ QOL [21].
Table 2 Studies using SF-36 matched with a case control
QOL domain (SF-36) Diniz Sérgi, 2007 [14] Kristina, 2007 [13] Bryant M, 2012 [18] Modersitziki F, 2014 [23•]
Stone patients
(p value)
Case
control
Stone patients
(p value)
Case
control
Stone patients
(p value)
Case
control
Stone patients
(p value)
USA mean
Physical function 70(<0.05) 95 84(>0.05) 84 75(<0.001) 84 34(<0.001) 50
Role-physical 25(<0.05) 100 82(>0.05) 81 68(<0.001) 81 38(<0.001) 50
Bodily pain 41(<0.05) 84 69(<0.05) 75 67(=0.003) 75 44(<0.001) 50
Gen health status 52(<0.05) 82 65(<0.05) 72 60(=0.001) 72 32(<0.001) 50
Virility 45(<0.05) 80 59(>0.05) 61 53(<0.001) 61 34(<0.001) 50
Social function 63(<0.05) 100 85(>0.05) 83 78 (=0.01) 83 39(<0.001) 50
Role-emotional 33(<0.05) 100 86(>0.05) 81 78 81 34(<0.001) 50
Mental Health 54(<0.05) 84 75(>0.05) 75 74 75 33(<0.001) 50
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Comparison and Outcomes of Different QOL Studies
There are a multitude of generic QOL tools; selecting a measure
can be difficult, as there are so many to choose from [4].
Examples of generic available measures are Short Form 36
(SF36) [5], Hospital and Anxiety Depression Scale (HADS)
[6] and Profile of Mood States (POMS) [7]. There is also a
QOL tool for patients with a ureteric stent in situ, the ureteric
stent specific questionnaire (USSQ) [8]. The four different tools
that where used in the literature in this review all have their own
advantages and disadvantages that are summarised in Table 3.
None of the tools used so far are perfect for assessing the QOL of
patients with KSD. Large numbers of patients suffer with KSD
[1•, 2, 3], and it has a huge impact on a person’s QOL [11–15,
16••, 18]. A disease-specific QOL tool that is universally used
would be useful to measure and compare QOL in these patients.
The most common QOL tool used in our literature review
for patients with KSD was the SF-36. As the SF-36 is a ge-
neric questionnaire, it does not target symptoms specific to
stone formers and may not be sensitive enough to measure
their QOL accurately [11]. However. when analysing the stud-
ies using the SF-36 questionnaire, we found a statistically
significant difference in the bodily pain and general health
sub domains (Table 2).
There are many disease-specific QOL tools [25], although
we could find none specifically designed for patients with
KSD that had been widely validated. One study [15] aimed
to fill this gap and produce a tool (theWinsicon Stone Quality
of life questionnaire), specifically for patients with KSD. They
also looked at asymptomatic stone formers in a paper pub-
lished in 2016, and they found that even if the person was
not aware of having KSD, but did have stones, they still had
a lower QOL in specific domains, particularly urinary fre-
quency, urgency, anxiety or nervousness (p = <0.027) [22].
In the limitations of these two studies, the authors identified
that further research into this area needs to include understand-
ing the role of comorbidities and social economic status in
patients with both symptomatic and asymptomatic stones, as
well as identifying the need for multi-institutional testing of
the WiSQoL questionnaire to validate it.
Limitations of the Study
The studies using the same QOL questionnaires did not assess
the data in a similar fashion, or compared the patients QOL to
the same ‘norm’. None of the studies made it clear if the
patient was having an active stone at the time of questionnaire
administration, or in the month prior (the SF-36 only measure
QOL in the 31 days prior to completing the questionnaire). It
is well recognised that recent procedures and ureteric stents
lower patients’ QOL and to avoid bias, we did not include
these studies in our review [17].
Some of the other limitations are the lack of stone charac-
teristics in the data provided, such as size, position and com-
position of stones. There were no randomised controlled trials
and all studies were of level 2a/b evidence.
A number of confounding factors associated with KSD can
also affect QOL of these patients. For example, obesity has
been shown to lower QOL [19] and is also known to be asso-
ciated with stone formers. One of the studies demonstrated that
QOL in stone formers was worse in women and in patients with
high BMIs [13]. Chronic diseases such as gout, diabetes, in-
flammatory bowel disease and bowel procedures are all associ-
ated with stone formation, but may themselves lower patients
QOL [20, 26, 27]. Other patient-related confounding factors
that may impact on measurement of QOL includes difficulty
completing the questionnaire, procedural and judgement issues.
Even with these limitations, seven [5, 12–15, 16••, 23•] out of
the nine studies demonstrated lower QOL in patients with KSD.
Areas of Future Research
Areas of future research could include evaluating theWisQOL
questionnaire over a larger and multi-institutional patient co-
hort. It would also be of benefit to look not just at health-
related QOL, including the physical, mental and emotional
burden of KSD to health, but also the financial impact, includ-
ing the loss of earnings to the individual as well as the finan-
cial cost on the health service. Donnally et al. in their longitu-
dinal evaluation of QOL using SF-36 found no significant
Table 3 Advantages and
disadvantages of current
questionnaire used
Questionnaire Advantages Disadvantages
SF-36 [5] • Covers wide range on QOL domains
• Widely used
• No KSD specific questions
Winsicon QOL in stones [16••] • Stone specific
• Treatment specific
• Not validated
• Large questionnaire
• Not broken into domains
• Difficult to analyse
Emory stone questionnaire [15] • Demographic specific
• Stone specific
• Not a QOL measurement
CES-D [24] • Specific for depression • No QOL domains
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changes in domains suggesting that a validated disease-
specific questionnaire might be better in these patients [11].
An important aspect of KSD is the affect to patients’ family
and wider concept of management of other associated medical
conditions either related to or contributing to KSD. Any QOL
study is perhaps incomplete without addressing some of these
factors. It is perhaps time that research and resource is allocat-
ed to generating patient-reported QOL outcomemeasures spe-
cific to KSD.
Conclusion
KSD affects QoL in most patients with most impact on bodily
pain and general health domains. Compared to the scale of
patients suffering from KSD, more work needs to be done in
measuring QOL both in terms of ‘Stone specific’ QOL mea-
suring tools and the quality/number of studies in this field.
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